Search results for "Malignant"

showing 10 items of 283 documents

Whole exome sequencing and system biology analysis support the "two-hit" mechanism in the onset of Ameloblastoma

2021

Background Ameloblastoma is the most frequent odontogenic tumor. Various evidence has highlighted the role of somatic mutations, including recurrent mutation BRAF V600E, in the tumorigenesis of Ameloblastoma, but the intact genetic pathology remains unknown. Material and Methods We sequenced the whole exome of both tumor tissue and healthy bone tissue from four mandibular ameloblastoma patients. The identified somatic mutations were integrated into Weighted Gene Co-expression Network Analysis on publicly available expression data of odontoblast, ameloblast, and Ameloblastoma. Results We identified a total of 70 rare and severe somatic mutations. We found BRAF V600E on all four patients, sup…

Proto-Oncogene Proteins B-rafOdontogenic TumorsBiologymedicine.disease_causeAmeloblastomaGermline mutationOral Cancer and Potentially malignant disordersExome SequencingmedicineGNAS complex locusspainHumansMissense mutationrisk factorsawarenessAmeloblastomaBiologyGeneral DentistryExomeExome sequencingUNESCO:CIENCIAS MÉDICASResearchoral cancermedicine.diseaseOtorhinolaryngologyMutationsurveys and questionnairesCancer researchbiology.proteinSurgeryCLTCCarcinogenesis
researchProduct

Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism.

2012

The phenolic phytoalexin resveratrol is well known for its health-promoting and anticancer properties. Its potential benefits are, however, limited due to its low bioavailability. Pterostilbene, a natural dimethoxylated analog of resveratrol, presents higher anticancer activity than resveratrol. The mechanisms by which this polyphenol acts against cancer cells are, however, unclear. Here, we show that pterostilbene effectively inhibits cancer cell growth and stimulates apoptosis and autophagosome accumulation in cancer cells of various origins. However, these mechanisms are not determinant in cell demise. Pterostilbene promotes cancer cell death via a mechanism involving lysosomal membrane …

PterostilbeneCancer Treatmentlcsh:MedicineApoptosisResveratrolBiochemistryLung and Intrathoracic Tumorschemistry.chemical_compoundMolecular cell biologyRNA interferenceNeoplasmsPhagosomesStilbenesDrug DiscoveryBreast TumorsBasic Cancer Researchlcsh:ScienceCytotoxicitySkin TumorsApoptotic Signaling CascadeCellular Stress ResponsesMultidisciplinaryMicroscopy ConfocalCell DeathMalignant MelanomaFlow CytometryCellular StructuresSignaling CascadesCell biologyEukaryotic CellsOncologyCaspasesMedicineCellular TypesCell DivisionResearch ArticleSignal TransductionProgrammed cell deathDrugs and DevicesDrug Research and DevelopmentMitosisAntineoplastic AgentsBiologyPermeabilityCell GrowthInhibitory Concentration 50NecrosisComplementary and Alternative MedicineCell Line TumorGastrointestinal TumorsAutophagyHumansHSP70 Heat-Shock ProteinsBiologyCell ProliferationDose-Response Relationship DrugL-Lactate DehydrogenaseCell growthlcsh:RAutophagyProteinsCancers and NeoplasmsRegulatory ProteinschemistrySubcellular OrganellesApoptosisResveratrolCancer celllcsh:QGene expressionLysosomesCytometryPloS one
researchProduct

Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.

2012

OBJECTIVES: The role of radical pleurectomy (RP) in the management of IMIG stage III in malignant pleural mesothelioma (MPM) remains controversial. The aim of the study was to investigate the feasibility and outcome as well as to determine factors predicting poor survival. METHODS: Patients having IMIG stage III MPM were identified within a prospective multimodality treatment study (RP followed by chemoradiation) between 2002 and 2010 at a single institution. Kaplan–Meier analyses, log-rank test and Cox regression analyses were used to estimate survival and to determine predictors of survival. RESULTS: A total of 78 patients (66.3 ± 2.5 years, 65 males) underwent RP followed by chemoradiati…

Pulmonary and Respiratory MedicineMaleMesotheliomamedicine.medical_specialtyLung NeoplasmsKaplan-Meier EstimatemedicineHumansMesotheliomaProgression-free survivalStage (cooking)LungAgedProportional Hazards ModelsUnivariate analysisProportional hazards modelbusiness.industryHazard ratioMesothelioma MalignantGeneral MedicineChemoradiotherapyMiddle Agedmedicine.diseaseSurgeryLog-rank testPleuraSurgeryFemaleCardiology and Cardiovascular MedicinebusinessOrgan Sparing TreatmentsChemoradiotherapyEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Cystic mucinous adenocarcinoma of the lung: a case report.

2011

Abstract Mucinous cystic tumors of the lung are uncommon, the preoperative pathologic diagnosis is difficult and their biological behavior is still controversial. We report the case of a patient with a clinically benign cystic lesion that post-operatively showed to be consistent with an invasive adenocarcinoma arising in a mucinous cystadenoma of the lung, We underline the difficulty of the clinical pre-operative diagnosis of this cystic neoplasia radiologically mimicking a hydatid cyst, and we report the negative TTF1 immunostaining potentially misleading in the differential diagnosis with metastatic mucinous carcinomas. Finallly, we evidence the presence of a pre-existing mucinous benign …

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsProliferation indexCystic mucinous adenocarcinoma lungSettore MED/21 - Chirurgia Toracicalcsh:SurgeryEnzyme-Linked Immunosorbent AssayCase ReportSettore MED/08 - Anatomia PatologicaMalignant transformationMetastasislcsh:RD78.3-87.3Diagnosis DifferentialFatal OutcomeCystadenoma MucinousBronchoscopymedicineAdenocarcinoma of the lungHumansMucinous cystadenomabusiness.industrylcsh:RD1-811General MedicineMiddle Agedmedicine.diseaseImmunohistochemistrylcsh:AnesthesiologyCystadenomaAdenocarcinomaSurgeryFemaleRadiologyDifferential diagnosisCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedJournal of cardiothoracic surgery
researchProduct

Age-related and tissue-specific accumulation of oxidative DNA base damage in 7,8-dihydro-8-oxoguanine-DNA glycosylase (Ogg1) deficient mice.

2001

Mutations that influence the repair of oxidative DNA modifications are expected to increase the steady-state (background) levels of these modifications and thus create a mutator phenotype that predisposes to malignant transformation. We have analysed the steady-state levels and repair kinetics of oxidative DNA modifications in cells of homozygous ogg1(-/-) null mice, which are deficient in Ogg1 protein, a DNA repair glycosylase that removes the miscoding base 8-hydroxyguanine (8-oxoG) from the genome. Oxidative purine modifications including 8-oxoG were quantified by means of an alkaline elution assay in combination with Fpg protein, the bacterial functional analogue of Ogg1 protein. In pri…

PurineMaleCancer ResearchGuanineDNA RepairOxidative phosphorylationBiologymedicine.disease_causeMalignant transformationchemistry.chemical_compoundMiceTranscription (biology)medicineAnimalsN-Glycosyl HydrolasesMice KnockoutCell growthAge FactorsGeneral MedicineDNAFibroblastsMolecular biologyOxygenOxidative StresschemistryDNA-Formamidopyrimidine GlycosylaseDNA glycosylaseOrgan SpecificityImmunologyHepatocytesOxidative stressDNACell DivisionDNA DamageCarcinogenesis
researchProduct

Buccodental health and oral mucositis. Clinical study in patients with hematological diseases

2006

Podeu consultar la versió en castellà a http://hdl.handle.net/2445/117376

RadiotherapyHematologic diseasesRadioteràpia:CIENCIAS MÉDICAS [UNESCO]chemoradiotherapyMucosa oralmucositisMalalties hematològiquesUNESCO::CIENCIAS MÉDICASQuimioteràpiaChemotherapyMalignant hematological diseasesOral mucosabuccodental status
researchProduct

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

2015

Abstract: Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation. In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients. Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC. Areas covered: This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-cl…

Receptor Protein-Tyrosine KinasesEntrectinibNTRK1NTRK2NTRK3Receptor tyrosine kinaseEntrectinibMalignant transformationAntineoplastic AgentNeoplasmsProtein-Tyrosine KinaseALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor; trkA; Receptor; trkB; Receptor; trkC; Pharmacology; Pharmacology (medical)Anaplastic Lymphoma KinasePharmacology (medical)salivary gland cancerProto-Oncogene ProteinbiologyTrkAPharmacology. TherapyTrkCTrkBGeneral MedicineProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinaseBenzamidesmedicine.symptomROS1ReceptorHumanIndazolesmedicine.drug_classprecision medicineAntineoplastic Agentscolorectal cancerBenzamideProto-Oncogene ProteinsmedicineROS1AnimalsHumansReceptor trkBReceptor trkCReceptor trkAnon-small cell lung cancerPharmacologyAnimalReceptor Protein-Tyrosine KinasesALK inhibitorIndazoleMechanism of actionALKTrk receptorbiology.proteinCancer researchNeoplasmALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor trkA; Receptor trkB; Receptor trkC; Pharmacology; Pharmacology (medical)Expert Opinion on Investigational Drugs
researchProduct

Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4

2007

Ines Gockel†, Carl C Schimanski, Markus Moehler & Theodor Junginger †Author for correspondence Johannes GutenbergUniversity of Mainz, Department of General and Abdominal Surgery, Langenbeckstr. 1, 55131 Mainz, Germany Tel.: +49 6131 177 291; Fax: +49 6131 176 630; gockel@ach.klinik.unimainz.de ‘The interaction between esophageal cancer-expressed CXCR4 and SDF-1α may have a key role in directing malignant cells to ‘homing’ organs ... thus, this mechanism may account for metastasis.’

Receptors CXCR4Cancer ResearchEsophageal Neoplasmsbusiness.industryAntineoplastic AgentsGeneral MedicineEsophageal cancermedicine.diseaseCXCR4Chemokine CXCL12Cyclin-Dependent KinasesNeoadjuvant TherapyhumanitiesChemokine receptorDrug Delivery SystemsOncologyCancer researchmedicineHumansMalignant cellsbusinessChemokines CXCHoming (hematopoietic)Future Oncology
researchProduct

Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review

2019

The clinical evolution of solitary fibrous tumor (SFT) remains unclear. Although various clinical, morphological and molecular criteria may indicate increased risk of malignancy, some SFT can still progress despite having a clearly benign appearance. Various risk stratification systems have been proposed, but unfortunately they are not sufficient to precisely determine the malignant potential. In this review, we discuss current knowledge on SFT, focusing on the following controversial issues: (i) the diverse morphologic spectrum: 'the great simulator;' (ii) malignant transformation or dedifferentiation; (iii) current risk stratification systems; and (iv) molecular factors associated with cl…

Risk0301 basic medicinePathologymedicine.medical_specialtySolitary fibrous tumorMalignancyPathology and Forensic MedicineMalignant transformationDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumansPathologicalbusiness.industrySoft tissueGeneral MedicineCell DedifferentiationPrognosismedicine.diseaseImmunohistochemistryCell Transformation Neoplastic030104 developmental biologyIncreased riskSolitary Fibrous Tumors030220 oncology & carcinogenesisRisk stratificationbusinessPathology International
researchProduct

Leptin and Its Receptor are Overexpressed in Brain Tumors and Correlate with the Degree of Malignancy

2009

Although leptin and its receptor (ObR) have emerged as important cancer biomarkers, the role of the leptin system in brain tumor development remains unknown. We screened 87 human brain tumor biopsies using immunohistochemistry and detected leptin and ObR in 55.2% and 60.9% cases, respectively. In contrast, leptin and ObR were absent in 14 samples of normal brain tissue. The presence of leptin correlated with ObR with overall concordance 80.5%. The leptin/ObR system was highly expressed in glioblastomas and anaplastic astrocytomas, while lower expression of both markers was noted in low-grade astrocytomas and gangliogliomas. The association between leptin/ObR and the degree of tumor malignan…

STAT3 Transcription Factornovel biomarkermedicine.medical_specialtyBlotting WesternBrain tumorFluorescent Antibody TechniqueCell CountBiologyleptinArticlePathology and Forensic MedicineCell Line TumorInternal medicinemedicineHumansleptin receptorProtein kinase BCell ProliferationLeptin receptorBrain NeoplasmsGeneral NeuroscienceLeptindigestive oral and skin physiologyglioblastomaBrainGliomamalignant progressionCell cyclemedicine.diseaseImmunohistochemistryOncogene Protein v-aktglioblastoma; leptin; leptin receptor; malignant progression; novel biomarkerKi-67 AntigenEndocrinologyTumor progressionReceptors LeptinImmunohistochemistryCancer biomarkersNeurology (clinical)hormones hormone substitutes and hormone antagonistsSignal TransductionBrain Pathology
researchProduct